What does Regeneron make?

Regeneron develops biologic medicines—particularly monoclonal antibodies—and has marketed therapies such as EYLEA for eye disease and Dupixent for inflammatory conditions.

How does Regeneron generate revenue?

Revenue mainly comes from sales of marketed drugs, plus collaboration and licensing income; commercial performance of a few big products materially influences results.

Is Regeneron profitable and growing?

Regeneron has delivered periods of strong revenue and profit growth driven by core products, but future growth depends on pipeline success and market conditions.

Does Regeneron pay a dividend?

Historically Regeneron has prioritised reinvesting in R&D and has not been known as a regular dividend payer; check the latest company announcements for current policy.

What are the main risks for investors?

Key risks include clinical trial failures, regulatory setbacks, competition, pricing and reimbursement pressures, patent expiries and general biotech sector volatility.

Regeneron Pharmaceuticals (REGN) Stock

Genetics-driven biotech firm treating eye and immune diseases. Here's the price, business snapshot, and what's worth knowing about Regeneron Pharmaceuticals in October 2026.

Regeneron Pharmaceuticals (REGN) is a US-based biotechnology company known for developing monoclonal antibody therapies and using human genetics to inform drug discovery. Its leading marketed products include EYLEA for retinal disease and Dupixent (co‑developed with Sanofi) for certain inflammatory conditions — both are material revenue drivers. The firm combines laboratory platforms (VelocImmune) and the Regeneron Genetics Center to identify and advance targets across ophthalmology, immunology, oncology and rare diseases. Investors should note Regeneron’s strengths in proprietary discovery technology and a deep pipeline, balanced by typical sector risks: R&D intensity, regulatory approval uncertainty, patent and pricing pressures, and possible revenue concentration around key drugs. With a market capitalisation near $61.4bn, the stock can be volatile around trial, approval and commercial updates. This summary is educational and not financial advice; consider your risk tolerance and consult a financial adviser to determine suitability.

Why It’s Moving

Regeneron Secures $8 Billion Immunology Expansion with Sanofi and Unveils Strong Clinical Data

Investors are reacting to a major strategic expansion of Regeneron’s alliance with Sanofi, which includes a $1 billion upfront payment and up to $7 billion in milestones for next-generation immunology antibodies. This deal is complemented by positive clinical trial results presented at ESMO and EASD, highlighting advancements in cancer treatments and muscle preservation therapies.

Sentiment:

🐃Bullish

Sanofi agreed to pay Regeneron $1 billion upfront and up to $7 billion in future milestones to add four long-acting immunology antibodies to their existing Dupixent partnership, establishing a 50:50 profit-sharing framework for these new assets.
Phase 3 data from the C-POST trial showcased longer-term survival outcomes for adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma, while initial studies on ubamatamab demonstrated durable responses in advanced low-grade serous ovarian cancer.
The Phase 2 COURAGE trial confirmed that trevogrumab prevented 70% of lean mass and muscle loss associated with semaglutide-induced weight loss, addressing a key concern in the rapidly growing GLP-1 market.

Regeneron Secures $8 Billion Immunology Expansion with Sanofi and Unveils Strong Clinical Data

Sentiment:

🐃Bullish

Sanofi agreed to pay Regeneron $1 billion upfront and up to $7 billion in future milestones to add four long-acting immunology antibodies to their existing Dupixent partnership, establishing a 50:50 profit-sharing framework for these new assets.
Phase 3 data from the C-POST trial showcased longer-term survival outcomes for adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma, while initial studies on ubamatamab demonstrated durable responses in advanced low-grade serous ovarian cancer.
The Phase 2 COURAGE trial confirmed that trevogrumab prevented 70% of lean mass and muscle loss associated with semaglutide-induced weight loss, addressing a key concern in the rapidly growing GLP-1 market.

Sixth Month Growth Performance

$744.51

+40.85 (5.81%)past 6 months

When is the next earnings date for REGENERON PHARMACEUTICALS INC (REGN)?

Regeneron Pharmaceuticals has a confirmed upcoming earnings report scheduled for October 30, 2026, before market opens. This release will cover the company's third-quarter fiscal results for 2026. Investors should note that this date aligns with the firm's historical pattern of reporting approximately three months after its previous quarterly update.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Regeneron Pharmaceuticals' stock with a target price of $927.45, indicating strong potential for growth.

Excellent

Financial Health

Regeneron is performing strongly, with impressive profits, revenue, and cash flow generation.

Below Average

Dividend

Regeneron Pharmaceuticals' low dividend yield of 0.48% indicates it may not be ideal for dividend-seeking investors. If you invested $1000 you would be paid $4.80 a year in dividends (based on the last 12 months).

Why You’ll Want to Watch This Stock

📈

Strong product drivers

EYLEA and Dupixent are significant revenue sources and shape near-term cashflow, though sales can be sensitive to competition and reimbursement changes.

⚡

Genetics-driven R&D

Regeneron’s genetics and VelocImmune platforms can accelerate target discovery and bespoke antibodies, offering scientific optionality while R&D outcomes remain uncertain.

🌍

Regulatory sensitivity

Product approvals, label changes and pricing decisions across markets materially affect valuation; investors should expect updates to move the share price.

Why invest with Nemo?

🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

Frequently asked questions

Regeneron Pharmaceuticals (REGN) Stock

Genetics-driven biotech firm treating eye and immune diseases. Here's the price, business snapshot, and what's worth knowing about Regeneron Pharmaceuticals in October 2026.

Why It’s Moving

Regeneron Secures $8 Billion Immunology Expansion with Sanofi and Unveils Strong Clinical Data

Sentiment:

🐃Bullish

Sanofi agreed to pay Regeneron $1 billion upfront and up to $7 billion in future milestones to add four long-acting immunology antibodies to their existing Dupixent partnership, establishing a 50:50 profit-sharing framework for these new assets.
Phase 3 data from the C-POST trial showcased longer-term survival outcomes for adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma, while initial studies on ubamatamab demonstrated durable responses in advanced low-grade serous ovarian cancer.
The Phase 2 COURAGE trial confirmed that trevogrumab prevented 70% of lean mass and muscle loss associated with semaglutide-induced weight loss, addressing a key concern in the rapidly growing GLP-1 market.

Regeneron Secures $8 Billion Immunology Expansion with Sanofi and Unveils Strong Clinical Data

Sentiment:

🐃Bullish

Sanofi agreed to pay Regeneron $1 billion upfront and up to $7 billion in future milestones to add four long-acting immunology antibodies to their existing Dupixent partnership, establishing a 50:50 profit-sharing framework for these new assets.
Phase 3 data from the C-POST trial showcased longer-term survival outcomes for adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma, while initial studies on ubamatamab demonstrated durable responses in advanced low-grade serous ovarian cancer.
The Phase 2 COURAGE trial confirmed that trevogrumab prevented 70% of lean mass and muscle loss associated with semaglutide-induced weight loss, addressing a key concern in the rapidly growing GLP-1 market.